pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Lantus
drug · protein
save

insulin glargine LA

pre_registrationupdated 6mo ago
by Gan & Lee Pharmaceuticals Co Ltd🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval24 co-mentions · 12 sources
  • drugSOLIQUA 100/3324 co-mentions · 12 sources
  • company$SNYSanofi12 co-mentions · 12 sources
  • company$SNYNFSanofi12 co-mentions · 12 sources
  • companySanofi-Aventis US LLC12 co-mentions · 12 sources
  • druginsulin glargine12 co-mentions · 12 sources
  • drugToujeo LA12 co-mentions · 12 sources
  • drug(insulin glargine + lixisenatide)12 co-mentions · 12 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.

targets

Insulin receptor

all catalysts(0)

nothing on the calendar yet

Trials studying insulin glargine LA

  • phase3Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetesnot yet recruitingn=450
  • phase1Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®completedn=114
  • phase4A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in Indiacompletedn=153
  • phase3AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medicationsrecruitingn=1,778
  • phase4A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellituscompletedn=105
  • phase3A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Beforecompletedn=1,085
  • phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetesrecruitingn=877
  • phase3A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)completedn=485

News(7)

  • Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
    The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.
    biospace · 1mo ago
  • STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
    Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each
    stat · 3mo ago
  • STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing
    Lilly was accused of charging “grossly” excessive prices for different insulin products that forced some patients to ration or forgo the drug.
    stat · 3mo ago
  • Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
    Sanofi is going to "look very deeply" at its late-stage pipeline as part of a portfolio prioritization initiative, though new CEO Belén Garijo didn’t commit to shelving a specific number of assets.
    biospace · 3mo ago
  • STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
    In a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugs
    stat · 3mo ago
  • A new, separate outbreak of the diarrhea-causing parasite
    A win for peptide proponents, autism advisory committees clash, and more health news from Morning Rounds
    stat · 3mo ago
  • STAT+: Popular insulin product enters shortage as other pens leave market
    The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.
    stat · 3mo ago
brand
Lantus
trade names
Abasaglar, Abasaglar (previously abasria), Abasaglar kwikpen, Basaglar, Ins lantus, Ins lantus opticlik
generic
insulin glargine
MOA
Insulin receptor agonist
indication
Type 1 Diabetes (Juvenile Diabetes)
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 7h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?